Methadone for cancer pain: What have we learned from clinical studies?

Abstract

The analgesic ladder guideline proposed by the World Health Organization has been shown to be effective in controlling cancer pain in about 80 percent of patients, but the remaining 20 percent still experience pain. Several strategies have been used to manage refractory cancer pain and opioid toxicity. Switching opioids, alternative routes of opioid administration, optimizing adjuvants, and invasive procedures are proposed treatments. Extensive medical literature corroborates each one of those treatments. Rotation from one opioid to another is a noninvasive strategy to overcome opioid side effects and refractory pain. Frequently, methadone is used during opioid rotation. However, there is a lack of consensus on how to proceed on rotation from morphine to methadone. In the current era of evidence-based medicine, the medical literature fails to answer some cancer pain-management issues. The purpose of this review is to clarify a process for transitioning from morphine to methadone.

Keywords

methadone opioids cancer pain palliative care opioid rotation

Get full access to this article

View all access options for this article.

References

Levy MH : Pharmacologic treatment of cancer pain. N Engl J Med. 1996; 335(15): 1124-1132.

Sykes J , Johnson R , Hanks GW : ABC of palliative care. Difficult pain problems. BMJ. 1997; 315(7112): 867-869.

Mercadante S , Portenoy RK : Opioid poorly-responsive cancer pain. Part 1: Clinical considerations. J Pain Symptom Manage. 2001; 21(2): 144-150.

Hanks GW , Forbes K : Opioid responsiveness. Acta Anaesthesiol Scand. 1997; 41(1 Pt 2): 154-158.

Kalso E , Heiskanen T , Rantio M , et al. : Epidural and subcutaneous morphine in the management of cancer pain: A double-blind cross-over study. Pain. 1996; 67(2-3): 443-449.

Nelson KA , Glare PA , Walsh D , et al. : A prospective within-patient, crossover study of continuous intravenous and subcutaneous morphine for chronic cancer pain. J Pain Symptom Manage. 1997; 13(5): 262-267.

Ischia S , Luzzani A , Maffezzolli GF , et al. : Percutaneous cordotomy: Technical considerations and results in 400 treated cases. In Rezzi R , Vissentin M (eds.): Pain Therapy. Amsterdam: Elsevier Biomedical Press, 1983.

Wang JK : Intrathecal morphine for intractable cancer pain secondary to cancer to the pelvic organs. Pain. 1985; 21(1): 99-102.

Mancini I , Lossignol DA , Body JJ : Opioid switch to oral methadone in cancer pain. Curr Opin Oncol. 2000; 12(4): 308-313.

10.

Mercadante S : Opioid rotation for cancer pain: Rationale and clinical aspects. Cancer. 1999; 86(9): 1856-1866.

11.

Pereira J , Lawlor P , Vigano , et al. : Equianalgesic dose ratios for opioids. A critical review and proposals for long-term dosing. J Pain Symptom Manage. 2001; 22(2): 672-687.

12.

Cherny NI : Opioid analgesics: Comparative features and prescribing guidelines. Drugs. 1996; 51(5): 713-737.

13.

Management of cancer pain: Adults. Agency for Health Care Policy and Research. Am J Hosp Pharm. 1994; 51(13): 1643-1656.

14.

Fainsinger R , Schoeller T , Bruera E : Methadone in the management of cancer pain: A review. Pain. 1993; 52(2): 137-147.

15.

Ripamonti C , Zecca E , Bruera E : An update on the clinical use of methadone for cancer pain. Pain. 1997; 70(2-3): 109-115.

16.

Agency for Health Care Policy Research : Management of Cancer Pain: Clinical Practice Guidelines. Rockville, MD: US Department of Health and Human Services, AHCPR Publications No. 940592, 1994.

17.

Twycross R , Lack S : Symptom control for advanced cancer. Pain Relief. London: Pitman Books, 1983.

18.

Lawlor P , Turner KS , Hanson J , et al. : Dose ratio between morphine and methadone in patients with cancer pain: A retrospective study. Cancer. 1998; 82(6): 1167-1173.

19.

Ripamonti C , Groff L , Brunelli C , et al. : Switching from morphine to oral methadone in treating cancer pain: What is the equianalgesic dose ratio? J Clin Oncol. 1998; 16(10): 3216-3321.

20.

Wheeler WL , Dickerson ED : Clinical applications of methadone. Am J Hosp Palliat Care. 2000; 17(3): 196-203.

21.

Bruera E , Neumann CM : Role of methadone in the management of pain in cancer patients. Oncology. 1999; 13(9): 1275-1282.

22.

Ripamonti C , De Conno F , Groff L , et al. : Equianalgesic dose/ratio between methadone and other opioid agonists in cancer pain: comparison of two clinical experiences. Ann Oncol. 1998; 9(1): 79-83.

23.

Gagnon B , Bruera E : Differences in the ratios of morphine to methadone in patients with neuropathic pain versus non neuropathic pain. J Pain Symptom Manage. 1999; 18(2): 120-125.

24.

Bruera E , Pereira J , Watanabe S , et al. : Opioid rotation in patients with cancer pain. A retrospective comparison of dose ratios between methadone, hydromorphone, and morphine. Cancer. 1996; 78(4): 852-857.

25.

Nauck F , Ostgathe C , Dickerson ED : A German model for methadone conversion. Am J Hosp Palliat Care. 2001; 18(3): 200-202.

26.

Ventafridda V , Ripamonti C , Bianchi M , et al. : A randomized study on oral administration of morphine and methadone in the treatment of cancer pain. J Pain Symptom Manage. 1986; 1(4): 203-207.

27.

De Conno F , Groff L , Brunelli C , et al. : Clinical experience with oral methadone administration in the treatment of pain in 196 advanced cancer patients. J Clin Oncol. 1996; 14(10): 2836-2842.

28.

Tse DM , Sham MM , Ng DK , et al. : An ad libitum schedule for conversion of morphine to methadone in advanced cancer patients: An open uncontrolled prospective study in a Chinese population. Palliat Med. 2003; 17(2): 206-211.

29.

Mercadante S , Casuccio A , Calderone L : Rapid switching from morphine to methadone in cancer patients with poor response to morphine. J Clin Oncol. 1999; 17(10): 3307-331230.

30.

Mercadante S , Bianchi M , Villari P , et al. : Opioid plasma concentration during switching from morphine to methadone: Preliminary data. Support Care Cancer. 2003; 11(5): 326-331.

31.

Mercadante S Casuccio A , Pumo S , et al. : Factors influencing the opioid response in advanced cancer patients with pain followed at home: The effects of age and gender. Support Care Cancer. 2000; 8(2): 123-130.

32.

Hagen N , Wasylenko E : Methadone: Outpatient titration and monitoring strategies in cancer patients. J Pain Symptom Manage. 1999; 18(5): 369-375.

33.

Mercadante S , Csuccio A , Fulfaro F , et al. : Switching from morphine to methadone to improve analgesia and tolerability in cancer patients: A prospective study. J Clin Oncol. 2001; 19(11): 2898-2904.

34.

Bell RF , Eccleston C , Kalso E : Ketamine as adjuvant to opioids for cancer pain. A qualitative systematic review. J Pain Symptom Manage. 2003; 26(3): 867-875.

35.

Moryl N , Santiago-Palma J , Kornick C , et al. : Pitfalls of opioid rotation: Substituting another opioid for methadone in patients with cancer pain. Pain. 2002; 96(3): 325-328.

36.

Soares LG : Poor social conditions, criminality and urban violence: Unmentioned barriers for effective cancer pain control at the end of life. J Pain Symptom Manage. 2003; 26(2): 693-695.

37.

Davis MP , Walsh D : Epidemiology of cancer pain and factors influencing poor pain control. Am J Hosp Palliat Care. 2004; 21(2): 137-142.

38.

Kornick CA , Kilborn MJ , Santiago-Palma J , et al. : QTc interval prolongation associated with intravenous methadone. Pain. 2003; 105(3): 499-506.

39.

Krantz MJ , Kutinsky IB , Robertson AD , et al. : Dose-related effects of methadone on QT prolongation in a series of patients with torsade de pointes. Pharmacotherapy. 2003; 23(6): 802-805.

40.

Gil M , Sala M , Anguera I , et al. : QT prolongation and Torsades de Pointes in patients infected with human immunodeficiency virus and treated with methadone. Am J Cardiol. 2003; 92(8): 995-997.